<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01869374</url>
  </required_header>
  <id_info>
    <org_study_id>6427</org_study_id>
    <nct_id>NCT01869374</nct_id>
  </id_info>
  <brief_title>Study Comparing Magnetic Seizure Therapy (MST) to Electroconvulsive Therapy (ECT) for Depression in Older Adults</brief_title>
  <acronym>MSTvsEST</acronym>
  <official_title>Improving Outcomes in Geriatric Depression: Magnetic Seizure Therapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>New York State Psychiatric Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>New York State Psychiatric Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the feasibility, tolerability and efficacy of Magnetic Seizure Therapy (MST) in
      elderly patients with a major depressive episode, who are randomly assigned to receive an
      acute course of MST or ECT.

      The investigators hypothesize:

        1. MST and ECT will have similar antidepressant efficacy

        2. MST will have less post-treatment amnesia than ECT as reflected in a primary measures of
           anterograde and retrograde amnesia following the acute treatment phase.

        3. At follow up, MST will show a lesser degree of persisting deficit in measures of
           retrograde amnesia than ECT.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to compare the clinical efficacy and side effects of Magnetic
      Seizure Therapy (MST) and Electroconvulsive Therapy (ECT) in older adults currently
      experiencing a major depressive episode in the context of either unipolar or bipolar
      depression. ECT is known to be highly effective in treating depression, but it can have some
      adverse cognitive side effects. MST is a new form of convulsive therapy that is being
      developed as a means of improving the side effect profile of ECT so that more patients may
      benefit without suffering significant detrimental effects on cognition.

      Both ECT and MST rely on a therapeutic seizure, but they do so in different ways. In ECT, an
      electrical stimulator is used to pass electrical current between two electrodes placed on the
      surface of person's head, which causes some electricity to go through the brain and cause a
      seizure. In MST, a magnetic stimulator is used to create a magnetic field in a targeted area
      of the brain, which induces a small electrical field in the neurons that causes a seizure.
      Treatments will be administered three times a week.

      In addition to the treatment sessions, this study will involve a number of assessments at
      different time-points (i.e., baseline prior to treatment, post-treatment, 2 months
      post-treatment and 6 months post-treatment) that are used to evaluate the person's
      antidepressant response and the physical and cognitive side effects of treatment.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2012</start_date>
  <completion_date type="Anticipated">July 2020</completion_date>
  <primary_completion_date type="Actual">July 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Electroconvulsive Therapy / Magnetic Seizure Therapy</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Hamilton Rating Scale for Depression, 24-Item (HRSD-24)</measure>
    <time_frame>baseline (pre-treatment) and post-treatment</time_frame>
    <description>The unabbreviated scale title is &quot;Hamilton Rating Scale for Depression.&quot; As its title suggests, this is a clinical measure of major depressive disorder.
The minimum score a participant could receive on this measure is 0. The maximum score that a participant could receive is 75. Please see a table written below that associates HRSD-24 values with clinical outcome:
0-7 = no depression 8-16 = mild depression 17-23 = moderate depression 24 and up = severe depression
Calculation details: Outcome data corresponds to baseline HRSD-24 score subtracted from post-tx HRSD-24 score. The larger difference, therefore, corresponds to the more effective treatment for this study.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">18</enrollment>
  <condition>Depression</condition>
  <condition>Major Depressive Episode</condition>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Magnetic Seizure Therapy (MST)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>MagVenture MagPro MST device</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RUL ECT</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Right Unilateral ECT with the Somatics Thymatron device using Ultrabrief stimulus</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>MagVenture MagPro MST</intervention_name>
    <description>Brain stimulation by magnetic means versus electrical standard unilateral Electroconvulsive Therapy (RUL ECT). Treatment will be administered 3 times a week.</description>
    <arm_group_label>Magnetic Seizure Therapy (MST)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>RUL ECT</intervention_name>
    <description>RUL ECT using the Somatics Thymatron device with Ultrabrief stimulus. Treatment will be administered 3 times a week.</description>
    <arm_group_label>RUL ECT</arm_group_label>
    <other_name>Right Unilateral Electroconvulsive Therapy</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 55-90

          -  Clinical diagnosis of major depressive episode, in the context of unipolar or bipolar
             disorder

          -  Willing and capable to provide informed consent

          -  Convulsive therapy clinically indicated

          -  Hamilton Rating Scale for Depression (HRSD24)≥ 20

          -  Mini Mental State Exam (MMSE) ≥ 24

          -  For outpatients: responsible adult living with the patient

        Exclusion Criteria:

          -  Current unstable or serious medical condition, or any comorbid medical condition that
             substantially increases the risks of ECT (such as acute myocardial infarction, space
             occupying brain lesion or other cause of increased intracranial pressure, unstable
             aneurysm or vascular malformation, poorly controlled diabetes mellitus, carcinoma,
             renal failure, hepatic failure)

          -  History of neurological disorder, epilepsy, stroke, brain surgery, metal in the head,
             history of known structural brain lesion

          -  Presence of devices that may be affected by MST (pacemaker, medication pump, cochlear
             implant, implanted brain stimulator, or vagus nerve stimulator implanted)

          -  History of head trauma with loss of consciousness for greater than 5 minutes

          -  History of schizophrenia, schizoaffective disorder, or rapid cycling bipolar disorder

          -  History of substance abuse or dependence in past 3 months

          -  Failure to respond to an adequate course of ECT in the current depressive episode

          -  History of ECT in the past 6 months and/or failure to respond to an adequate trial of
             ECT lifetime

          -  Presence of intracardiac lines
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefan B Rowny, MD, MFA</last_name>
    <role>Principal Investigator</role>
    <affiliation>NYSPI/Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>New York State Psychiatric Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10032</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Rowny, S., &amp; Lisanby, S. H. (2009). Other Brain Stimulation Methods. In B. J. Sadock, V.A. Sadock &amp; P. Ruiz (Eds.) . Kaplan and Sadock's Comprehensive Textbook of Psychiatry (9th ed.) (Pp. 3301-3314). Lippincott Williams &amp; Wilkins. Philadelphia:PA.</citation>
  </reference>
  <reference>
    <citation>Rowny SB, Benzl K, Lisanby SH. Translational development strategy for magnetic seizure therapy. Exp Neurol. 2009 Sep;219(1):27-35. doi: 10.1016/j.expneurol.2009.03.029. Epub 2009 Apr 5. Review.</citation>
    <PMID>19348798</PMID>
  </reference>
  <reference>
    <citation>McClintock SM, DeWind NK, Husain MM, Rowny SB, Spellman TJ, Terrace H, Lisanby SH. Disruption of component processes of spatial working memory by electroconvulsive shock but not magnetic seizure therapy. Int J Neuropsychopharmacol. 2013 Feb;16(1):177-87. doi: 10.1017/S1461145711001866. Epub 2012 Jan 5.</citation>
    <PMID>22217479</PMID>
  </reference>
  <reference>
    <citation>Rowny SB, Cycowicz YM, McClintock SM, Truesdale MD, Luber B, Lisanby SH. Differential heart rate response to magnetic seizure therapy (MST) relative to electroconvulsive therapy: a nonhuman primate model. Neuroimage. 2009 Sep;47(3):1086-91. doi: 10.1016/j.neuroimage.2009.05.070. Epub 2009 Jun 2.</citation>
    <PMID>19497373</PMID>
  </reference>
  <reference>
    <citation>Rowny, S., &amp; Lisanby, S. H. (2008). Brain Stimulation in Psychiatry. In A. Tasman, J. Kay, J. A. Lieberman, M. B. First &amp; M. Maj (Eds.), Psychiatry (3rd ed.) (pp.2354-2371). Chichester, UK: John Wiley &amp; Sons. DOI: 10.1002/9780470515167.ch109</citation>
  </reference>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 22, 2013</study_first_submitted>
  <study_first_submitted_qc>June 4, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2013</study_first_posted>
  <results_first_submitted>February 27, 2020</results_first_submitted>
  <results_first_submitted_qc>June 3, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 19, 2020</results_first_posted>
  <last_update_submitted>June 3, 2020</last_update_submitted>
  <last_update_submitted_qc>June 3, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>New York State Psychiatric Institute</investigator_affiliation>
    <investigator_full_name>Stefan Rowny</investigator_full_name>
    <investigator_title>Assistant Professor of Clinical Psychiatry</investigator_title>
  </responsible_party>
  <keyword>Depression</keyword>
  <keyword>Brain Stimulation</keyword>
  <keyword>Seizure therapy</keyword>
  <keyword>Convulsive Therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Seizures</mesh_term>
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Informed Consent Form</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 28, 2016</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT01869374/ICF_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 11, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/74/NCT01869374/Prot_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Five-day washout from all anti-depressants and mood stabilizers.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Magnetic Seizure Therapy (MST)</title>
          <description>MagVenture MagPro MST device
MagVenture MagPro MST: Brain stimulation by magnetic means versus electrical standard unilateral Electroconvulsive Therapy (RUL ECT). Treatment will be administered 3 times a week.</description>
        </group>
        <group group_id="P2">
          <title>RUL ECT</title>
          <description>Right Unilateral ECT with the Somatics Thymatron device using Ultrabrief stimulus
RUL ECT: RUL ECT using the Somatics Thymatron device with Ultrabrief stimulus. Treatment will be administered 3 times a week.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Magnetic Seizure Therapy (MST)</title>
          <description>MagVenture MagPro MST device
MagVenture MagPro MST: Brain stimulation by magnetic means versus electrical standard unilateral Electroconvulsive Therapy (RUL ECT). Treatment will be administered 3 times a week.</description>
        </group>
        <group group_id="B2">
          <title>Right Unilateral ECT (RUL ECT)</title>
          <description>Right Unilateral ECT with the Somatics Thymatron device using Ultrabrief stimulus
RUL ECT: RUL ECT using the Somatics Thymatron device with Ultrabrief stimulus. Treatment will be administered 3 times a week.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="18"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.3" lower_limit="56" upper_limit="79"/>
                    <measurement group_id="B2" value="65.3" lower_limit="58" upper_limit="74"/>
                    <measurement group_id="B3" value="65.8" lower_limit="56" upper_limit="79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="11"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="9"/>
                    <count group_id="B2" value="9"/>
                    <count group_id="B3" value="18"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Hamilton Rating Scale for Depression, 24-Item (HRSD-24)</title>
        <description>The unabbreviated scale title is &quot;Hamilton Rating Scale for Depression.&quot; As its title suggests, this is a clinical measure of major depressive disorder.
The minimum score a participant could receive on this measure is 0. The maximum score that a participant could receive is 75. Please see a table written below that associates HRSD-24 values with clinical outcome:
0-7 = no depression 8-16 = mild depression 17-23 = moderate depression 24 and up = severe depression
Calculation details: Outcome data corresponds to baseline HRSD-24 score subtracted from post-tx HRSD-24 score. The larger difference, therefore, corresponds to the more effective treatment for this study.</description>
        <time_frame>baseline (pre-treatment) and post-treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Magnetic Seizure Therapy (MST)</title>
            <description>MagVenture MagPro MST device
MagVenture MagPro MST: Brain stimulation by magnetic means versus electrical standard unilateral Electroconvulsive Therapy (RUL ECT). Treatment will be administered 3 times a week.</description>
          </group>
          <group group_id="O2">
            <title>RUL ECT</title>
            <description>Right Unilateral ECT with the Somatics Thymatron device using Ultrabrief stimulus
RUL ECT: RUL ECT using the Somatics Thymatron device with Ultrabrief stimulus. Treatment will be administered 3 times a week.</description>
          </group>
        </group_list>
        <measure>
          <title>Hamilton Rating Scale for Depression, 24-Item (HRSD-24)</title>
          <description>The unabbreviated scale title is &quot;Hamilton Rating Scale for Depression.&quot; As its title suggests, this is a clinical measure of major depressive disorder.
The minimum score a participant could receive on this measure is 0. The maximum score that a participant could receive is 75. Please see a table written below that associates HRSD-24 values with clinical outcome:
0-7 = no depression 8-16 = mild depression 17-23 = moderate depression 24 and up = severe depression
Calculation details: Outcome data corresponds to baseline HRSD-24 score subtracted from post-tx HRSD-24 score. The larger difference, therefore, corresponds to the more effective treatment for this study.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.625" lower_limit="16" upper_limit="29"/>
                    <measurement group_id="O2" value="15.375" lower_limit="2" upper_limit="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Adverse event data for participants was collected from baseline to post-treatment (between two and three months, depending on the participants' number of treatments).</time_frame>
      <desc>This study did not include a design for monitoring or assessing adverse events. We did not consider any of our participants to be at risk of serious adverse events or all-cause mortality. Prior to enrollment in the study, all our participants were evaluated by a physician and anesthesiologist and were medically cleared to receive an acute course of convulsive therapy. Any risk that would have been contraindicated with convulsive therapy was ruled out in advance of participants' pre-tx scan.</desc>
      <group_list>
        <group group_id="E1">
          <title>Magnetic Seizure Therapy (MST)</title>
          <description>MagVenture MagPro MST device
MagVenture MagPro MST: Brain stimulation by magnetic means versus electrical standard unilateral Electroconvulsive Therapy (RUL ECT). Treatment will be administered 3 times a week.</description>
        </group>
        <group group_id="E2">
          <title>RUL ECT</title>
          <description>Right Unilateral ECT with the Somatics Thymatron device using Ultrabrief stimulus
RUL ECT: RUL ECT using the Somatics Thymatron device with Ultrabrief stimulus. Treatment will be administered 3 times a week.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="18"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Stefan Rowny, MD</name_or_title>
      <organization>New York State Psychiatric Institute</organization>
      <phone>(646) 774-5417</phone>
      <email>stefan.rowny@nyspi.columbia.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

